ImaginAb is a bio-imaging company, which focuses on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. The Company designs and develops a pipeline of imaging products that use the specificity of monoclonal antibodies to create precise images of disease activity. Its programs include a portfolio of precision imaging products, such as CD8 (IAB22M2C) and CD4 for immune-oncology; and PSMA PET (IAB2M) for prostate cancer.